Skip to content

Verification of Pulse Oximetry in Neonatal Population

Verification of Pulse Oximetry in Neonatal Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00751439
Enrollment
25
Registered
2008-09-12
Start date
2008-06-30
Completion date
2009-09-30
Last updated
2010-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Keywords

Oximeter, Arterial blood gas, comparison

Brief summary

The purpose of this his post-market, observational study titled Verification of Pulse Oximetry in the Neonatal Population is to gather data to further support the accuracy of Nonin's pulse oximeters when used in the neonate population. Neonates who are currently undergoing arterial blood gas (ABG) sampling, as part of their medical care will be recruited to participate in this study for collecting opportunity samples. Nonin's PureLight® noninvasive sensor will be applied to a foot of the neonate; an adhesive wrap secures the sensor to the neonate. The sensor immediately begins obtaining SpO2 and pulse rate measurements which are sent to the oximeter module for display on the Electronic Data Collection System (EDCS). At the time the prescribed ABG is drawn, the EDCS must have a marker captured to identify the end of the ABG for SpO2 comparison. The SpO2 accuracy of pulse oximeter will be measured by comparing SpO2 readings of the pulse oximeter to values of SaO2 (opportunity samples) determined by a CO-oximeter.

Interventions

None listed

Sponsors

Children's Hospitals and Clinics of Minnesota
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 30 Days
Healthy volunteers
No

Inclusion criteria

* Gestational age: 25 weeks to full term * Weight range: No minimum or maximum range * Age: up to 1 month (30 DAYS) * Gender: Both * ABGs as part of their medical care, to be analyzed by co-oximeter * Consent signed by at least one legal guardian

Exclusion criteria

* Presence of any skin irritation or breakdown on the foot * Foot impediments which would preclude proper placement of the sensor * Clinical condition precluding the use of adhesive materials * Cessation of ABGs during study enrollment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026